Patents by Inventor Benjamin J. CHEN

Benjamin J. CHEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240174649
    Abstract: Disclosed herein are compounds that inhibit cullin-RING E3 ubiquitin ligase 4, a method of inhibiting the catalytic activity of a Cullin-RING E3 Ubiquitin (Ub) Ligase (CRL) in a cell, compositions comprising the inhibitor compounds, a method of treating a tumor, and a method of treating a subject for cancer.
    Type: Application
    Filed: February 1, 2022
    Publication date: May 30, 2024
    Inventors: Robert J. DEVITA, Zhen-Qiang PAN, Khoi Q. HUYNH, Moses MOUSTAKIM, Kenneth WU, Chalada SUEBSUWONG, Benjamin D. HOPKINS, Peng-Jen CHEN, Michael Block LAZARUS
  • Publication number: 20240127451
    Abstract: Described herein are methods and computer systems for classification of CD8 T-cell topology using a patient response-based linear cutoff model. A plurality of histology images of tissue samples in a plurality of patients are received by a computer system. An image analysis of the plurality of histology images is performed to obtain a CD8+ T-cell abundance in the tumor parenchyma and stroma in each of the plurality of histology images. Real inflammation scores and tumor infiltration scores are determined based on a polar coordinate transformation of the CD8+ T-cell abundance in the tumor parenchyma and stroma. Based on the real inflammation scores and tumor infiltration scores, a feature space is generated, and linear boundaries or linear cutoffs between a plurality of classifications in the feature space are identified based on the real inflammation scores, the tumor infiltration scores, and patient response data.
    Type: Application
    Filed: February 25, 2022
    Publication date: April 18, 2024
    Applicant: Bristol-Myers Squibb Company
    Inventors: George C. Lee, Robin Edwards, Scott Ely, Daniel N. Cohen, John B. Wojcik, Vipul A. Baxi, Dimple Pandya, Jimena Trillo-Tinoco, Benjamin J. Chen, Andrew Fisher, Falon Gray
  • Publication number: 20230326022
    Abstract: A method includes receiving an input histology image, processing, using a cell classification model, the input histology image to generate one or more lymphocyte density maps within the input histology image, and performing morphological image processing on the one or more lymphocyte density maps to identify one or more TLS regions within the input histology image. Each TLS region is represented by a respective cluster of lymphocyte cells. For each corresponding TLS region of the one or more TLS regions identified in the input histology image, the method also includes extracting, from the respective cluster of lymphocyte cells, a respective set of TLS features, and processing, using a TLS classification model, the respective set of TLS features to classify the corresponding TLS region as one of a first TLS maturation state, a second TLS maturation state, or a third TLS maturation state.
    Type: Application
    Filed: April 7, 2023
    Publication date: October 12, 2023
    Applicants: Bristol-Myers Squibb Company, PathAI, Inc.
    Inventors: Vanessa Matos-Cruz, George Lee, Varsha Chinnaobireddy, Maryam Pouryahya, Darren Thomas Fahy, Christian Winskell Kirkup, Kathleen Sucipto, Sai Chowdary Gullapally, Archit Khosla, Nishant Agrawal, Benjamin Patrick Glass, Sergine Brutus, Limin Yu, Murray Berle Resnick, Rachel L. Sargent, Vipul Atulkumar Baxi, Scott Ely, Benjamin J. Chen
  • Publication number: 20230303700
    Abstract: The present disclosure provides methods of identifying a subject suitable for an anti-PD-?PD-L1 antagonist therapy comprising measuring assay CD8 localization and PD-L1 expression in a tumor sample obtained from the subject. In some aspects, method further comprises administering (i) an anti-PD-?PD-L1 antagonist therapy or (ii) an anti-PD-?PD-L1 antagonist and anti-CT-LA-4 antagonist combination therapy to a subject identified as having a tumor exhibiting an excluded CD8 localization phenotype, wherein the tumor is PD-L1 negative.
    Type: Application
    Filed: August 31, 2021
    Publication date: September 28, 2023
    Applicant: Bristol-Myers Squibb Company
    Inventors: George C. LEE, Robin EDWARDS, Scott ELY, Daniel N. COHEN, John B. WOJCIK, Vipul A. BAXI, Dimple PANDYA, Jimena TRILLO-TINOCO, Benjamin J. CHEN, Andrew FISHER, Falon GRAY
  • Publication number: 20230306762
    Abstract: Described herein are methods and computer systems for classification of CD8 T-cell topology using artificial intelligence and machine learning. A plurality of histology images of tissue samples in a plurality of patients are received by a computer system. An image analysis of the plurality of histology images is performed to obtain a CD8+ T-cell abundance in the tumor parenchyma and stroma in each of the plurality of histology images. A machine learning algorithm is then trained using results of the image analysis and the CD8+ T-cell abundance in the tumor parenchyma and stroma. Based on the training, a machine learning feature space comprising a plurality of classifications is generated, and boundaries between the plurality of classifications in the machine learning feature space are identified.
    Type: Application
    Filed: August 31, 2021
    Publication date: September 28, 2023
    Applicant: Bristol-Myers Squibb Company
    Inventors: George C. LEE, Robin EDWARDS, Scott ELY, Daniel N. COHEN, John B. WOJCIK, Vipul A. BAXI, Dimple PANDYA, Jimena TRILLO-TINOCO, Benjamin J. CHEN, Andrew FISHER, Falon GRAY
  • Patent number: D1019023
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: March 19, 2024
    Assignee: Amazon Technologies, Inc.
    Inventors: Michael Edward James Paterson, Chia-Wei Chan, Mei Hsuan Chen, Benjamin Wild, Matthew J. England, Wen-Yo Lu, James Siminoff, Mark Siminoff, Yen-Chi Tsai